Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Australia's CSL Buys 80% Stake in China Blood Products Company for $352 Million

publication date: Jun 13, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Australia's CSL Limited will pay $352 million to acquire an 80% controlling stake in Wuhan Zhong Yuan Rui De Biological Products (Ruide) from China's Humanwell Healthcare Group. For 20 years, CSL has been supplying Ruide with albumin, the plasma that contains red blood cells. CSL also has the right to buy the remaining 20% of Ruide for $120 million in three years. Over time, CSL plans to move directly into the China plasma fractionation market, including plasma collection, with a complete portfolio of products. More details....

Stock Symbols: (ASX: CSL; USOTC: CSLLY) (SHA: 600079)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...